Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 243Squamous Cell Carcinoma of Head and Neck 137Melanoma 137Parkinson Disease 4, Autosomal Dominant Lewy Body 119Neoplasm Metastasis 105Triple Negative Breast Neoplasms 96Neoplasms 90Lung Neoplasms 88Breast Neoplasms 79Colorectal Neoplasms 70Carcinoma, Renal Cell 69Head and Neck Neoplasms 59Urinary Bladder Neoplasms 50Stomach Neoplasms 48Ovarian Neoplasms 46Endometrial Neoplasms 45Carcinoma, Transitional Cell 44Carcinoma, Hepatocellular 35Uterine Cervical Neoplasms 34Pancreatic Neoplasms 34Esophageal Neoplasms 27Recurrence 25Prostatic Neoplasms 25Carcinoma, Squamous Cell 25Carcinoma 25Sarcoma 24Brain Neoplasms 23Glioblastoma 22Hodgkin Disease 19Cholangiocarcinoma 19

Interventions

pembrolizumab 4Cyclophosphamide 4Radiotherapy 3Cisplatin 3fludarabine 2Doxorubicin 2Carboplatin 2zimberelimab 1olaparib 1lenvatinib 1envafolimab 1avelumab 1Thymectomy 1Taxes 1Sunitinib 1Robotic Surgical Procedures 1Ramucirumab 1Radiotherapy, Adjuvant 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Etoposide 1Drug Therapy 1Chemoradiotherapy 1Cetuximab 1AP 1903 reagent 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Thymoma × pembrolizumab × 1 year × Clear all
NCT03463460 2026-03-23

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
9 enrolled
Thoracic

Thymoma

NCT04710628 2026-02-19

PECATI

MedSIR

Phase 2 Completed
43 enrolled
Thoracic

Thymoma

NCT03295227 2026-01-30

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
37 enrolled
Thoracic

Thymoma

NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis

Phase 1 Active not recruiting
126 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Intestinal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Nasopharyngeal Neoplasms, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Skin Neoplasms, Thymoma, Thymus Neoplasms, Colorectal Neoplasms, Adenocarcinoma, Clear Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡